JO
ZNTL icon

John Overdeck’s Zentalis Pharmaceuticals ZNTL Stock Holding History

John Overdeck’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Buy
3,024,936
+68,410
+2% +$273K 0.01% 1246
2026
Q1 		$6.92M Buy
2,956,526
+1,485,112
+101% +$3.84M 0.01% 1706
2025
Q4 		$1.99M Buy
1,471,414
+108,067
+8% +$157K ﹤0.01% 2437
2025
Q3 		$2.06M Buy
1,363,347
+270,294
+25% +$405K ﹤0.01% 2106
2025
Q2 		$1.27M Buy
1,093,053
+543,719
+99% +$717K ﹤0.01% 2115
2025
Q1 		$873K Sell
549,334
-67,466
-11% -$145K ﹤0.01% 2252
2024
Q4 		$1.87M Sell
616,800
-291,801
-32% -$956K ﹤0.01% 1767
2024
Q3 		$3.34M Sell
908,601
-143,797
-14% -$523K 0.01% 1322
2024
Q2 		$4.3M Buy
1,052,398
+807,403
+330% +$9.02M 0.01% 1076
2024
Q1 		$3.86M Buy
+244,995
New +$3.37M 0.01% 1108
2023
Q4 		– Sell
-109,429
Closed -$2.2M – 3425
2023
Q3 		$2.2M Buy
109,429
+92,729
+555% +$2.35M 0.01% 1319
2023
Q2 		$471K Buy
+16,700
New +$401K ﹤0.01% 2359
2022
Q2 		– Sell
-94,502
Closed -$4.36M – 3001
2022
Q1 		$4.36M Buy
94,502
+80,349
+568% +$4.33M 0.01% 983
2021
Q4 		$1.19M Sell
14,153
-144,823
-91% -$11.2M ﹤0.01% 2394
2021
Q3 		$10.6M Buy
158,976
+30,105
+23% +$1.74M 0.02% 753
2021
Q2 		$6.86M Buy
+128,871
New +$6.9M 0.02% 1005
2021
Q1 		– Sell
-57,031
Closed -$2.96M – 4318
2020
Q4 		$2.96M Buy
+57,031
New +$2.57M 0.01% 1244

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

John Overdeck's ZNTL Position: Q2 2026 in Review

John Overdeck increased its Zentalis Pharmaceuticals (ZNTL) stake by 2.3% in Q2 2026, buying an estimated $273K and bringing the position to 3,024,936 shares worth $14.7M. The position accounts for 0.01% of the portfolio, ranked #1246.

John Overdeck first reported a position in ZNTL in Q4 2020 and has held it in 17 quarters since. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • John Overdeck held 3,024,936 shares of Zentalis Pharmaceuticals worth $14.7M as of Q2 2026.
  • John Overdeck bought 68,410 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $273K.
  • Zentalis Pharmaceuticals made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1246 holding.
  • John Overdeck first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.